Cite

HARVARD Citation

    van den Heuvel, L. et al. (n.d.). Eculizumab therapy monitoring: Residual hemolysis in alternative pathway test is not caused by C5 activity. Molecular immunology. pp. 226-. [Online]. 
  
Back to record